BioMarin Finalizes $4.8 Billion Acquisition of Amicus Therapeutics

Key Facts

1BioMarin Pharmaceutical completed the acquisition of Amicus Therapeutics in an all-cash transaction for a total equity value of approximately $4.8 billion.

2The acquisition was executed at $14.50 per share, adding Galafold, Pombiliti, and Opfolda to BioMarin's commercial portfolio.

BioMarin Pharmaceutical Inc. has officially completed its acquisition of Amicus Therapeutics in an all-cash transaction valued at approximately $4.8 billion. The deal was executed at a price of $14.50 per share, significantly expanding BioMarin's footprint in the biotechnology sector. By integrating Amicus, BioMarin adds key treatments such as Galafold, Pombiliti, and Opfolda to its commercial portfolio, targeting Fabry and Pompe diseases. This strategic move is expected to provide immediate revenue-generating assets and bolster the company's long-term market position. BioMarin has indicated that it expects to update its fiscal year 2026 financial guidance following the successful closing of the deal. The acquisition underscores the ongoing consolidation trend within the global healthcare and biopharma industries.